Introduction {#s0005}
============

The prevalence of type 2 diabetes mellitus is rapidly rising worldwide [@bib1]. The total number of people with diabetes globally is projected to increase from 171 million in 2000 to 366 million in 2030 [@bib2]. The burden of diabetes and its complications may double in the span of 30 years. Diabetic nephropathy (DN) is the leading cause of renal replacement therapy and affects approximately 40% of type 1 and type 2 diabetic patients [@bib3]. DN is also one of the most common causes of renal replacement therapy disease in Korea (45.4%) [@bib4].

However, not all nephropathies in diabetic patients are due to DN. The prevalence of nondiabetic nephropathy (NN) is presumed to exist in between one-sixth and two-thirds of diabetic patients with overt proteinuria [@bib5], [@bib6], [@bib7], [@bib8]. In Korea, Kim et al. [@bib9] reported 74 cases of renal biopsy performed in diabetic patients, and nearly half of them had NN.

It is important to distinguish between NN and DN because some NNs are reversible, whereas DN rarely improves. However, it is difficult to differentiate between these two diseases based on clinical findings alone. Renal biopsy is recommended if diabetic patients present with an atypical course of nephropathy. However, this procedure is invasive and might lead to some complications.

Although several studies have been performed to evaluate the prevalence and predictors of NN in diabetic patients, there are no definitive indications for renal biopsy. In previous studies, predictors of NN included evidence of acute renal failure, microscopic hematuria, short duration of diabetes, absence of retinopathy, or nephritic proteinuria [@bib9], [@bib10], [@bib11].

We evaluated the prevalence and clinical characteristics of NN in type 2 diabetes mellitus patients who underwent renal biopsy. We analyzed the significance of renal biopsy and immunosuppressive treatment in NN with type 2 diabetes mellitus patients.

Methods {#s0010}
=======

Data were collected retrospectively from medical records at Chungnam National University Hospital. All patients were diagnosed with type 2 diabetes mellitus prior to renal biopsy or during the admission period. Our dataset included renal biopsies from January 1994 to December 2010. Exclusion criteria were as follows: (1) patients with kidney transplants who had undergone renal biopsy for diagnosis of rejection; (2) patients who had undergone renal biopsy for distinguishing subtype of lupus nephritis; and (3) patients who had undergone renal biopsy of renal tumors. Ninety-four diabetic patients who underwent renal biopsy were screened, and 19 patients were excluded.

The reasons for renal biopsy were as follows: (1) nephrotic range proteinuria (\>3 g/day) with atypical course of nephropathy; (2) proteinuria without diabetic retinopathy \[urine total protein (TP)\>500 mg/24 hours or spot urine TP/creatinine (Cr)\>500 mg/g\]; (3) unexplained abrupt decline in renal function \[decrease to\>50% of estimated glomerular filtration rate (eGFR) or increase to\>200% of serum creatinine within 1 month\]; (4) unexplained hematuria (\>3/high power field); and (5) proteinuria with short duration of diabetes (24 hour urine TP\>500 mg or spot urine TP/Cr\>500 mg/g within 5 years after diabetes diagnosis).

All biopsy specimens were obtained via percutaneous needle biopsy and analyzed via light microscopy, electron microscopy, and immunofluorescence. All diagnoses were confirmed by the same experienced renal pathologist. DN was diagnosed by the presence of mesangial expansion and diffuse intercapillary glomerulosclerosis with or without the nodular Kimmelstiel--Wilson formation, basement membrane thickening, fibrin caps, or capsular drops. Nondiabetic renal diseases were categorized following orthodox pathological criteria.

Based on the biopsy findings, the patients were classified into three groups: Group I (isolated DN); Group II \[NN with underlying DN (DN+NN)\]; and Group III (isolated NN).

Patient characteristics analyzed included: age at biopsy, sex, duration of diabetes (years), presence of diabetic retinopathy, HbA1c (%), 24-hour urine total protein (mg/day), blood urea nitrogen (BUN, mg/dL), serum creatinine (mg/dL), albumin (g/L), triglyceride (mg/dL), total cholesterol (mg/dL), C-reactive protein (CRP, mg/dL) as a marker of inflammation, complement (C3, C4, mg/dL), and immunoglobulin (Ig) G/A/M (mg/dL). Estimated GFR (mL/min/1.73 m^2^) was calculated by Modification of Diet in Renal Disease (MDRD) equation. Baseline characteristics and renal outcomes after the follow-up period (decline of eGFR\>50% from baseline eGFR) were analyzed. Baseline was defined as the latest data prior to renal biopsy.

Patients with NN (Groups II and III; *n*=65) were then reclassified into two groups based on treatment modalities (i.e., immunosuppressant or glucocorticoid therapy vs. conservative measures).

Treatment modalities and renal outcomes in patients with NN were analyzed. Renal outcomes were evaluated by changes of eGFR and proteinuria. Treatment response group was defined as proteinuria\<3.5 g/day and least 50% reduction from initial value and stable renal function from baseline (change in creatinine\<25%), or improvement of eGFR\>50% from baseline over a 6-month period of observation.

*Statistical analysis*

Collected data were processed using Microsoft Office Excel 2010, IBM SPSS Statistics version 20, and PASW(Predictive Analytics SoftWare) Statistics 18. Quantitative data are expressed as mean±standard deviation. Negative or positive values were expressed as count/total sample counts. Comparisons between groups were assessed using an unpaired *t* test, analysis of variance, Chi-squared test, nonparametric test. Relationships between baseline characteristics and renal outcomes were assessed using binary univariate and multivariate regression analysis. A *P* value\<0.05 was considered statistically significant.

Results {#s0015}
=======

Reasons for renal biopsy {#s0020}
------------------------

Seventy-five renal biopsies among 75 diabetic patients were performed during the study period. Ten patients were categorized into Group I (isolated DN), 11 patients into Group II (DN+NN), and 54 patients into Group III (isolated NN).

The reasons for renal biopsy are shown in [Table 1](#t0005){ref-type="table"}. Among them, nephrotic range proteinuria with atypical course of diabetic nephropathy was the most common (44.0%). Proteinuria without diabetic retinopathy and unexplained decline in renal function were both ranked second (20.0%, each). The other reasons for biopsy included unexplained microscopic hematuria (13.3%) and proteinuria with short duration of diabetes (2.7%; [Table 1](#t0005){ref-type="table"}).

Patients with nephrotic range proteinuria with an atypical course, proteinuria without diabetic retinopathy, unexplained decline in renal function, or unexplained microscopic hematuria had significantly higher incidences of NN (Group III) compared to the DN or combined groups (Groups I and II).

Baseline characteristics {#s0025}
------------------------

Duration of diabetes (*P*=0.008) and prevalence of diabetic retinopathy (*P*=0.008) were significantly lower in Group III compared to Groups I and II. The patients in Group II had the lowest eGFR, whereas those in Group III had the highest level of eGFR (*P*=0.022). No other laboratory parameters showed significant differences (*P*\>0.05, [Table 2](#t0015){ref-type="table"}).

Results of renal biopsy {#s0030}
-----------------------

[Table 3](#t0020){ref-type="table"} presents the pathologic diagnoses and reasons for renal biopsy in NNs (isolated DN is excluded from this table). The three most common NNs were membranous nephropathy (23.1%), IgA nephropathy (21.5%), and acute tubulointerstitial nephritis (15.4%). Nephrotic range proteinuria was the most common reason for renal biopsy in cases of membranous nephropathy and IgA nephropathy. Unexplained decline of renal function was the most common reason for renal biopsy in acute tubulointerstitial nephritis.

Renal outcomes and clinical characteristics in NN {#s0035}
-------------------------------------------------

The overall median follow-up duration was 38 months, and those in Group I, Group II, and Group III were 23 months, 26 months, and 50.5 months, respectively. Group III had the best long-term renal survival rate, and Group II had the worst long-term renal survival rates. Renal deterioration was defined as decline the of eGFR\>50% from the baseline ([Fig. 1](#f0005){ref-type="fig"}).

Compared to the nonimproved renal outcome group, improved renal outcome group showed lower prevalence of DN (*P*=0.001), more intensive treatment (*P*=0.010, [Table 4](#t0025){ref-type="table"}, [Table 5](#t0030){ref-type="table"}).

Treatment modalities and renal outcomes in NNs {#s0040}
----------------------------------------------

During the maximal follow-up (up to 5 years), 31 patients were treated with intensive methods (i.e., immunosuppressants, glucocorticoids, or combination therapy), and 22 patients (70.9%) achieved improvement in renal function and proteinuria. Thirty-four patients were treated with conservative methods, and 13 patients (38.2%) achieved renal improvement. Intensive treatment methods showed more favorable renal outcome in univariate regression analysis. Long-term survival did not show statistical significant differences between the two groups (*P*=0.9315, [Fig. 2](#f0010){ref-type="fig"}).

Three patients in the isolated nondiabetic renal disorder group (Group III) showed remarkable improvement in eGFR at the 6-month follow-up period, even with a baseline eGFR\>15 mL/min/1.73m^2^. Two patients were diagnosed with focal segmental glomerulosclerosis, and another was diagnosed with IgA nephropathy. One of the focal segmental glomerulosclerosis patients received a combination therapy of corticosteroid, rituximab, and mycophenolic acid, whereas the other patient received corticosteroid only. The patient with IgA nephropathy was treated with cyclophosphamide only. Group II patients (DN+NN) did not show such a significant improvement in eGFR.

Renal outcomes of intensive treatment group {#s0045}
-------------------------------------------

We evaluated several factors to find a prognostic factor in NN in diabetes patients with intensive treatment. In the intensive treatment group, clinical parameters, and renal outcomes were analyzed using binomial logistic regression (dependent variable: treatment response group). Absence of diabetic retinopathy was associated with favorable renal outcome in intensive treatment group ([Table 6](#t0035){ref-type="table"}).

Discussion {#s0050}
==========

It is important to distinguish NN from DN because some cases of NN are reversible, whereas DN is rarely improves.

Several clinical scenarios supportive of NN include rapidly decreasing kidney function with or without increasing proteinuria (particularly if nephritic), active urinary sediment, evidence of other systemic disease, absence of diabetic retinopathy, and proteinuria in a type 1 diabetic patient with\<5 years of disease duration [@bib12], [@bib13], [@bib14].

Although several studies have been performed to evaluate clinical predictors of NN in diabetic patients, there is no definitive indication for renal biopsy in diabetic patients with proteinuria or declining renal function.

In this study, patients with isolated NN had a shorter duration of diabetes and less diabetic retinopathy, consistent with findings in preceding studies. The isolated NN group also showed higher baseline eGFR compared to other groups, which was not demonstrated in previous studies [@bib8], [@bib9], [@bib15], [@bib16].

Chong et al. [@bib10] suggested that the presence of diabetic retinopathy and longer duration of diabetes may be predictors of DN, whereas acute renal failure and microscopic hematuria may be predictors of NN. Kim et al. [@bib9] and Soni et al. [@bib11] suggested that a shorter duration of diabetes, absence of retinopathy, and absence of nephritic proteinuria may be predictors of NN. Monga et al. [@bib17] analyzed superimposed glomerulopathies on diabetic glomerulosclerosis (DGS) and suggested that duration of diabetes favors superimposition of glomerulonephritis on DGS.

However, some studies did not show such correlations. Hayashi et al. [@bib18] analyzed renal biopsy specimens of Japanese DM patients, and found that duration of DM was not associated with all morphologic parameters. A study by Lin et al. [@bib19] demonstrated that diabetic retinopathy was not exclusively seen in NN among type 2 DM patients. Mak et al. [@bib20] suggested that DN and NN were associated with similar durations of disease, as well as incidences of retinopathy and neuropathy.

There were no statistically significant differences between our three study groups regarding age, HbA1c, creatinine level, or 24-hour urine total protein. Our population characteristics were similar to the study of NN in type II DM patients by Zajjari et al. [@bib21]. Mak et al. [@bib20] also found that patients with both isolated DN and NN had no difference in serum creatinine or glycosylated hemoglobin levels. Ghani et al. [@bib22] did not find significant differences between DGS and NN groups according to age or serum creatinine.

In this study, the prevalence of biopsy-proven NN in diabetic patients was 86.7%, which was higher than previously reported findings. The variety in reported prevalence of NN is mainly due to a varying selection criteria for renal biopsy [@bib5], [@bib6], [@bib7], [@bib8], [@bib23]. Therefore, it may be helpful to collect more valuable prognostic data.

Furthermore, renal outcomes in NN patients were analyzed according to the treatment method. This emphasizes the importance of confirming the diagnosis of NN including via renal biopsy in diabetic patients, as well as the application of intensive treatments such as immunosuppressants or glucocorticoids. Wong et al. [@bib8] suggested that the presence of DGS is a risk factor for end-stage renal disease compared to NN. Kim et al. [@bib9] demonstrated that half of diabetic patients who were treated with immunosuppressants achieved complete remission of NN.

In this study, we observed impressively better renal outcomes in patients who treated with intensive treatment including corticosteroid or immunosuppressants. Compared to the nonimproved renal outcome group, improved renal outcome group showed lower prevalence of diabetic nephropathy and more intensive treatment. This suggests that intensive treatment including corticosteroid or immunosuppressants should be recommended for type 2 diabetic patients with NN, even though the patients has poor initial renal function confirmed at the diagnosis.

Absence of diabetic retinopathy was associated with favorable renal outcome in the intensive treatment group. It is possible that absence of diabetic retinopathy is a prognostic factor for a good effect of intensive treatment.

There are several limitations to this study. First, the retrospective study design allows for findings to be subject to many other variables not analyzed in this study. Next, the number of male patients was much higher than that of females, making our results less generalizable. Further evaluation of predictors and prognostic factor of NN such as larger multicenter prospective trials or meta-analyses of existing studies might be helpful.

In conclusion, renal biopsy should be recommended for type 2 diabetic patients with atypical nephropathy because a considerable number of diabetic patients may have NNs that are reversible. Intensive treatment including corticosteroid or immunosuppressants could be recommended for type 2 diabetic patients with NN, especially if the patients do not have diabetic retinopathy.
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![**Renal outcomes of patients during follow-up (median 38.0 months).** Group 3 showed the best renal survival rate among the three groups. Group II showed the largest proportion of renal deterioration during follow-up \[*P\<*0.0001 by Log Rank (Mantel--Cox)\]. Key: Group 1, diabetic nephropathy; Group 2, underlying diabetic nephropathy+superimposed nondiabetic nephropathy; Group 3, nondiabetic nephropathy.](gr1){#f0005}

![**Renal outcomes of patients according to treatment modality (median 40.0 months).** The patients who treated with intensive methods showed slightly better renal survival rate than the patients who treated with conservative methods \[*P=*0.9315 by Log Rank (Mantel--Cox)\].](gr2){#f0010}

###### 

Reasons for renal biopsy in type 2 diabetic patients[⁎](#tbl1fn1a){ref-type="table-fn"}, [†](#tbl1fn1b){ref-type="table-fn"}

  Reason for renal biopsy                                     Group I (*n=*10)   Group II (*n=*11)   Group III (*n=*54)   *P*[‡](#t0010){ref-type="table-fn"}
  ----------------------------------------------------------- ------------------ ------------------- -------------------- -------------------------------------
  Nephrotic range proteinuria with atypical course (*n=*33)   5 (15.2)           8 (24.2)            20 (60.6)            0.003
  Proteinuria without diabetic retinopathy (*n=*15)           2 (13.3)           1 (6.7)             12 (80.0)            0.001
  Unexplained decline of renal function (*n=*15)              1 (6.7)            1 (6.7)             13 (86.7)            \<0.001
  Unexplained hematuria (*n=*10)                              1 (10.0)           1 (10.0)            8 (80.0)             0.007
  Proteinuria with short duration of diabetes (*n=*2)         1 (50.0)           0 (0)               1 (50.0)             NS

Data are presented as *n* (%).

DN, diabetic nephropathy; NN, nondiabetic nephropathy; NS, nonsignificant value.

Differences in prevalence among the three groups were analyzed separately with nonparametric tests according to reason for biopsy.

Group I: DN, Group II: DN+NN, Group III: NN.

*P*=0.514 by Fisher′s exact test.

###### 

Baseline characteristics of type 2 diabetic patients who underwent renal biopsy

  Parameter                   Group I (*n=*10)                                 Group II (*n=*11)                                Group III (*n=*54)                                *P*
  --------------------------- ------------------------------------------------ ------------------------------------------------ ------------------------------------------------- -------
  Age (y)                     65.0±13.1[⁎](#tbl2fn2a){ref-type="table-fn"}     53.2±14.9                                        54.6±14.1[⁎](#tbl2fn2a){ref-type="table-fn"}      NS
  M:F ratio                   9:1                                              10:1[⁎](#tbl2fn2a){ref-type="table-fn"}          1.35:1[⁎](#tbl2fn2a){ref-type="table-fn"}         0.024
  DM duration (y)             8.3±7.5                                          9.6±7.9                                          4.2±4.8                                           0.008
  Presence of DR              5/9 (55.6)                                       7/10 (70.0)[⁎](#tbl2fn2a){ref-type="table-fn"}   11/46 (23.9)[⁎](#tbl2fn2a){ref-type="table-fn"}   0.008
  Laboratory data HbA1c (%)   7.11±1.60                                        7.17±1.30                                        6.87±1.28                                         NS
  24 h UP (mg/d)              5274.2±5749.5                                    4564.5±2354.6                                    4077.3±5372.6                                     NS
  eGFR (mL/min/1.73m^2^)      51.0±31.0                                        33.4±21.1[⁎](#tbl2fn2a){ref-type="table-fn"}     61.5±31.9[⁎](#tbl2fn2a){ref-type="table-fn"}      0.022
  BUN (mg/dL)                 26.3±15.1^⁎^                                     42.4±16.0[⁎](#tbl2fn2a){ref-type="table-fn"}     26.8±19.2[⁎](#tbl2fn2a){ref-type="table-fn"}      0.037
  Cr (mg/dL)                  2.1±1.4                                          3.2±2.4                                          2.0±2.0                                           NS
  Albumin (g/L)               3.2±1.1                                          2.9±0.7                                          3.2±1.0                                           NS
  TG (mg/dL)                  256.9±126.7[⁎](#tbl2fn2a){ref-type="table-fn"}   145.7±55.9[⁎](#tbl2fn2a){ref-type="table-fn"}    252.6±237.9                                       NS
  Total cholesterol (mg/dL)   224.7±95.0                                       197.2±49.5                                       234.3±137.9                                       NS
  CRP (mg/dL)                 0.2±0.1                                          1.4±3.1                                          1.4±3.3                                           NS
  C3 (mg/dL)                  87.0±19.4                                        103.4±22.6                                       101.5±30.6                                        NS
  C4 (mg/dL)                  36.6±9.0                                         36.9±9.4                                         30.7±17.2                                         NS
  IgG (mg/dL)                 967.7±375.9                                      1179.0±535.4                                     1072.4±537.8                                      NS
  IgA (mg/dL)                 273.7±120.5                                      347.8±194.6                                      304.5±145.3                                       NS
  IgM (mg/dL)                 92.0±65.0                                        126.6±98.0                                       139.4±77.4                                        NS

Data are presented as mean±SD or positive count/total count (%).

BUN, blood urea nitrogen; Cr, creatinine; CRP, C-reactive protein; DM, diabetes mellitus; DR, diabetic retinopathy; Ig, immunoglobulin; NS, nonsignificant value; UP, urine total protein.

Statistically significant findings in analysis between two groups: between Groups I and II -- serum BUN (*P=*0.029), triglyceride (*P=*0.025); between Groups I and III -- age at biopsy (*P=*0.039); and between Groups II and III -- sex (*P=*0.036), presence of diabetic retinopathy (*P=*0.016), baseline eGFR (*P=*0.002), serum BUN (*P=*0.012).

###### 

Results of renal biopsy in nondiabetic nephropathy[⁎](#tbl3fn3a){ref-type="table-fn"}

  Pathology         Total (*n=*65)   A           B          C           D          E
  ----------------- ---------------- ----------- ---------- ----------- ---------- ---------
  MN                15 (23.1)        8 (53.3)    5 (33.3)   0 (0)       1 (6.7)    1 (6.7)
  IgA nephropathy   14 (21.5)        6 (42.9)    3 (21.4)   3 (21.4)    2 (14.3)   0 (0)
  ATIN              10 (15.4)        4 (40.0)    1 (10.0)   4 (40.0)    1 (10.0)   0 (0)
  FSGS              6 (9.2)          3 (50.0)    1 (16.7)   2 (33.3)    0 (0)      0 (0)
  MCD               5 (7.7)          1 (20.0)    2 (40.0)   1 (20.0)    1 (20.0)   0 (0)
  HSP nephritis     4 (6.2)          2 (50.0)    0 (0)      1 (25.0)    1 (25.0)   0 (0)
  DPGN              3 (4.6)          1 (33.3)    1 (33.3)   0 (0)       1 (33.3)   0 (0)
  MesPGN            2 (3.1)          1 (50.0)    0 (0)      0 (0)       1 (50.0)   0 (0)
  ANCA-GN           2 (3.1)          0 (0)       0 (0)      2 (100.0)   0 (0)      0 (0)
  HT nephropathy    2 (3.1)          0 (0)       0 (0)      1 (50.0)    1 (50.0)   0 (0)
  MPGN              1 (1.5)          1 (100.0)   0 (0)      0 (0)       0 (0)      0 (0)
  IgM nephropathy   1 (1.5)          1 (100.0)   0 (0)      0 (0)       0 (0)      0 (0)

Data are presented as *n* (%).

ATIN, acute tubulointerstitial nephritis; DPGN, diffuse proliferative glomerulonephritis; FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; HSP, Henoch--Schönlein purpura; HT, hypertensive; MCD, minimal change disorder; MesPGN, mesangial proliferative glomerulonephritis; MN, membranous nephropathy; MPGN, membranous proliferative glomerulonephritis.

A, Nephrotic range proteinuria (\>3 g/day) with atypical course; B, Proteinuria without diabetic retinopathy \[urine total protein (TP)\>500 mg/day or spot urine TP/Cr\>500 mg/g\]; C, Unexplained decline of renal function; D, Unexplained hematuria (\>3 red blood cells/high-power field); E, Proteinuria with short duration of diabetes (24 h urine TP\>500 mg or spot urine TP/creatinine \>500 mg/g within 5 years of diabetes).

###### 

Univariate (binomial) logistic regression analysis (NDRD and renal outcome)[⁎](#tbl4fn4a){ref-type="table-fn"}

                            Odds ratio   95% CI          *P*
  ------------------------- ------------ --------------- -------
  Age (y)                   1.028        0.990--1.066    NS
  DM duration (y)           0.904        0.816--1.001    NS
  Presence of DR            0.360        0.112--1.155    NS
  Presence of DN            0.053        0.006--0.447    0.007
  Aggressive treatment      5.077        1.696--15.195   0.004
  24 h UP (mg/d)            1.000        1.000--1.000    NS
  HbA1c (%)                 0.967        0.646--1.447    NS
  eGFR (mL/min/1.73 m^2^)   0.100        0.997--1.031    NS
  Albumin (g/L)             0.844        0.501--1.422    NS
  TG (mg/dL)                1.003        0.999--1.007    NS
  CRP (mg/dL)               1.083        0.887--1.322    NS

CI, confidence interval; Cr, creatinine; CRP, C-reactive protein; DN, diabetic nephropathy; DR, diabetic retinopathy; eGFR, estimated glomerular filtration rate; NDRD, nondiabetic renal diseases; NS, not significant; TG, triglyceride; UP, urine total protein.

Treatment response: proteinuria \<3.5 g/day and least 50% reduction from initial value, and stable renal function from baseline (change in Cr\<25%), or improvement of eGFR\>50% from baseline over a 6-month period of observation.

###### 

Multivariate logistic regression analysis results (NDRD and renal outcome)[⁎](#tbl5fn5a){ref-type="table-fn"}

                         Odds ratio   95% CI          *P*
  ---------------------- ------------ --------------- -------
  Presence of DN         0.055        0.006--0.502    0.010
  Aggressive treatment   4.931        1.464--16.611   0.010

CI, confidence intervals; DN, diabetic nephropathy; NDRD, nondiabetic renal diseases.

Treatment response: proteinuria \<3.5 g/day and least 50% reduction from initial value, and stable renal function from baseline (change in creatinine \<25%), or improvement of estimated glomerular filtration rate \>50% from baseline over a 6-month period of observation.

###### 

Univariate (binomial) logistic regression analysis (NDRD and renal outcome in intensive treatment group)[⁎](#tbl6fn6a){ref-type="table-fn"}

                            Odd ratio   95% CI         *P*
  ------------------------- ----------- -------------- -------
  Age (y)                   1.074       0.994--1.161   NS
  DM duration (y)           0.940       0.798--1.109   NS
  Presence of DR            0.114       0.016--0.828   0.032
  Presence of DN            0.000       0.000          NS
  24 h UP (mg/d)            1.000       1.000--1.000   NS
  HbA1c (%)                 1.376       0.606--3.123   NS
  eGFR (mL/min/1.73 m^2^)   1.010       0.983--1.038   NS
  Albumin (g/L)             1.701       0.531--5.450   NS
  TG (mg/dL)                1.005       0.997--1.013   NS
  CRP (mg/dL)               1.036       0.801--1.340   NS

CI, confidence intervals; Cr, creatinine; CRP, C-reactive protein; DN, diabetic nephropathy; DR, diabetic retinopathy; eGFR, estimated glomerular filtration rate; NDRD, nondiabetic renal diseases; NS, not significant; TG, triglyceride; UP, urine total protein.

Treatment response: proteinuria \<3.5 g/day and least 50% reduction from initial value, and stable renal function from baseline (change in creatinine\<25%), or improvement of eGFR\>50% from baseline over a 6-month period of observation.
